Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update
NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward a pivotal, late-stage study. For small drug developers without a marketed product, one clinical readout can reset expectations fast. Pancreatic cancer is a tough proving ground. Survival gains are hard to show, and investors tend to discount early-stage results until
